News & Updates

Show Multimedia Only

How effective are COVID-19 mRNA vaccines in children?

20 Mar 2026 by

Immunization with COVID-19 mRNA vaccines is safe and provides a small protective benefit in children aged 6‒17 years, as shown in a Spain study.

How effective are COVID-19 mRNA vaccines in children?

20 Mar 2026

Meta-analysis supports use of dupilumab in first-line treatment of prurigo nodularis

20 Mar 2026

In patients with prurigo nodularis, treatment with dupilumab provides consistent, meaningful improvements in pruritus while having a favourable safety profile, according to a meta-analysis.

Meta-analysis supports use of dupilumab in first-line treatment of prurigo nodularis

20 Mar 2026

Novel single-tablet BIC/LEN noninferior to standard of care in PWH

20 Mar 2026 by

A single-tablet regimen (STR) combining bictegravir and lenacapavir (BIC/LEN) was noninferior to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in maintaining virologic suppression among people with HIV (PWH) who are virologically suppressed, according to the ARTISTRY-2 trial presented at CROI 2026.

Novel single-tablet BIC/LEN noninferior to standard of care in PWH

20 Mar 2026

Switch from oral to injectable ART maintains viral suppression, highly acceptable to teens

19 Mar 2026 by

In adolescents with well-controlled HIV, switching from an oral antiretroviral therapy (ART) regimen to the long-acting injectable cabotegravir plus rilpivirine combination appears to be not only safe and efficacious in maintaining viral suppression but also strongly favoured, according to the end-of-study data from the phase I/II IMPAACT 2017 study.

Switch from oral to injectable ART maintains viral suppression, highly acceptable to teens

19 Mar 2026

Use of rhGM-CSF promotes wound healing via macrophage immunomodulation

19 Mar 2026

Topical administration of recombinant human granulocyte macrophage–colony stimulating factor (rhGM-CSF) helps induce healing of diabetic and nondiabetic wounds, suggests a study.

Use of rhGM-CSF promotes wound healing via macrophage immunomodulation

19 Mar 2026

Sivelestat helps mitigate ARDS risk in cardiovascular procedures

19 Mar 2026

Treatment with sivelestat in patients undergoing cardiovascular procedures appears to lower the incidence of acute respiratory distress syndrome (ARDS) and all-cause mortality, as reported in a study.

Sivelestat helps mitigate ARDS risk in cardiovascular procedures

19 Mar 2026

Original New Drug Application Approvals by US FDA (16-28 February 2026)

19 Mar 2026

New drug applications approved by US FDA as of 16-28 February 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-28 February 2026)

19 Mar 2026

Original New Drug Application Approvals by US FDA (1-15 March 2026)

19 Mar 2026

New drug applications approved by US FDA as of 1-15 March 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (1-15 March 2026)

19 Mar 2026

Bladder-sparing regimen for MIBC shows promising antitumour activity

18 Mar 2026 by

In the treatment of patients with muscle-invasive bladder cancer (MIBC), a perioperative regimen of the antibody–drug conjugate sacituzumab govitecan plus pembrolizumab yields a promising clinical complete response rate without eliciting grade ≥4 adverse events (AEs), allowing bladder preservation without further therapy in some patients, according to the phase II SURE-02 trial.

Bladder-sparing regimen for MIBC shows promising antitumour activity

18 Mar 2026

Pemivibart prevents COVID-19 in people with advanced HIV

18 Mar 2026 by

Individuals living with advanced HIV infection who received pemivibart demonstrate good tolerability, with no cases of RT-PCR-confirmed symptomatic COVID-19 reported through month 6, as shown by the results of a subgroup analysis of the CANOPY study.

Pemivibart prevents COVID-19 in people with advanced HIV

18 Mar 2026

News & Updates

Showing Pharmacy articles

Showing

Specialty:

How effective are COVID-19 mRNA vaccines in children?

How effective are COVID-19 mRNA vaccines in children?

Meta-analysis supports use of dupilumab in first-line treatment of prurigo nodularis

Meta-analysis supports use of dupilumab in first-line treatment of prurigo nodularis

Novel single-tablet BIC/LEN noninferior to standard of care in PWH

Novel single-tablet BIC/LEN noninferior to standard of care in PWH

Switch from oral to injectable ART maintains viral suppression, highly acceptable to teens

Switch from oral to injectable ART maintains viral suppression, highly acceptable to teens

Use of rhGM-CSF promotes wound healing via macrophage immunomodulation

Use of rhGM-CSF promotes wound healing via macrophage immunomodulation

Sivelestat helps mitigate ARDS risk in cardiovascular procedures

Sivelestat helps mitigate ARDS risk in cardiovascular procedures

Original New Drug Application Approvals by US FDA (16-28 February 2026)

Original New Drug Application Approvals by US FDA (16-28 February 2026)

Original New Drug Application Approvals by US FDA (1-15 March 2026)

Original New Drug Application Approvals by US FDA (1-15 March 2026)

Bladder-sparing regimen for MIBC shows promising antitumour activity

Bladder-sparing regimen for MIBC shows promising antitumour activity

Pemivibart prevents COVID-19 in people with advanced HIV

Pemivibart prevents COVID-19 in people with advanced HIV